Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease - Université de Lorraine
Article Dans Une Revue Advances in Therapy Année : 2021

Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease

Résumé

In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn's disease. We present the health-related quality of life and work productivity improvement results with upadacitinib from CELEST.
ClinicalTrials.gov identifier, NCT02365649.

Dates et versions

hal-04214958 , version 1 (22-09-2023)

Identifiants

Citer

Laurent Peyrin-Biroulet, Edouard Louis, Edward Loftus, Ana Lacerda, Qian Zhou, et al.. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease. Advances in Therapy, 2021, 38 (5), pp.2339-2352. ⟨10.1007/s12325-021-01660-7⟩. ⟨hal-04214958⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

More